207 related articles for article (PubMed ID: 36925069)
21. Multicentric analytical comparability study of programmed death-ligand 1 expression on tumor-infiltrating immune cells and tumor cells in urothelial bladder cancer using four clinically developed immunohistochemistry assays.
Schwamborn K; Ammann JU; Knüchel R; Hartmann A; Baretton G; Lasitschka F; Schirmacher P; Braunschweig T; Tauber R; Erlmeier F; Hieke-Schulz S; Weichert W
Virchows Arch; 2019 Nov; 475(5):599-608. PubMed ID: 31267201
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of PD-1 Inhibitors in First-Line Treatment for Advanced Gastroesophageal Junction and Gastric Cancer by Subgroups: A Systematic Review and Meta-Analysis.
Fei S; Lu Y; Chen J; Qi J; Wu W; Wang B; Han Y; Wang K; Han X; Zhou H; Wang J; Chen J
Chemotherapy; 2023; 68(4):197-209. PubMed ID: 37331333
[TBL] [Abstract][Full Text] [Related]
23. A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non-Small Cell Lung Cancer.
Rimm DL; Han G; Taube JM; Yi ES; Bridge JA; Flieder DB; Homer R; West WW; Wu H; Roden AC; Fujimoto J; Yu H; Anders R; Kowalewski A; Rivard C; Rehman J; Batenchuk C; Burns V; Hirsch FR; Wistuba II
JAMA Oncol; 2017 Aug; 3(8):1051-1058. PubMed ID: 28278348
[TBL] [Abstract][Full Text] [Related]
24. Equivalence of laboratory-developed test and PD-L1 IHC 22C3 pharmDx across all combined positive score indications.
Vainer G; Huang L; Emancipator K; Nuti S
PLoS One; 2023; 18(6):e0285764. PubMed ID: 37267266
[TBL] [Abstract][Full Text] [Related]
25. A comparability study of immunohistochemical assays for PD-L1 expression in hepatocellular carcinoma.
Shi L; Zhang SJ; Chen J; Lu SX; Fan XJ; Tong JH; Chow C; Tin EK; Chan SL; Chong CC; Lai PB; To KF; Wong N; Chan AW
Mod Pathol; 2019 Nov; 32(11):1646-1656. PubMed ID: 31231126
[TBL] [Abstract][Full Text] [Related]
26. Comparison of assessment of programmed death-ligand 1 (PD-L1) status in triple-negative breast cancer biopsies and surgical specimens.
Noske A; Steiger K; Ballke S; Kiechle M; Oettler D; Roth W; Weichert W
J Clin Pathol; 2024 Mar; 77(4):239-245. PubMed ID: 36669878
[TBL] [Abstract][Full Text] [Related]
27. Programmed death ligand-1 (PD-L1) clone 22C3 expression in resected colorectal cancer as companion diagnostics for immune checkpoint inhibitor therapy: A comparison study and inter-rater agreement evaluation across proposed cut-offs and predictive (TPS, CPS and IC) scores.
Lea D; Zaharia C; Søreide K
Cancer Treat Res Commun; 2024; 38():100788. PubMed ID: 38150845
[TBL] [Abstract][Full Text] [Related]
28. Comparison of three PD-L1 immunohistochemical assays in head and neck squamous cell carcinoma (HNSCC).
de Ruiter EJ; Mulder FJ; Koomen BM; Speel EJ; van den Hout MFCM; de Roest RH; Bloemena E; Devriese LA; Willems SM
Mod Pathol; 2021 Jun; 34(6):1125-1132. PubMed ID: 32759978
[TBL] [Abstract][Full Text] [Related]
29. PD-L1 Immunohistochemistry in Gastric Cancer: Comparison of Combined Positive Score and Tumor Area Positivity Across 28-8, 22C3, and SP263 Assays.
Klempner SJ; Cowden ES; Cytryn SL; Fassan M; Kawakami H; Shimada H; Tang LH; Wagner DC; Yatabe Y; Savchenko A; Salcius J; Johng D; Chen J; Montenegro G; Moehler M
JCO Precis Oncol; 2024 Jun; 8():e2400230. PubMed ID: 38822761
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of an online training tool for scoring programmed cell death ligand-1 (PD-L1) diagnostic tests for lung cancer.
Jasani B; Bänfer G; Fish R; Waelput W; Sucaet Y; Barker C; Whiteley JL; Walker J; Hovelinck R; Diezko R
Diagn Pathol; 2020 Apr; 15(1):37. PubMed ID: 32303234
[TBL] [Abstract][Full Text] [Related]
31. Immuno-Oncology Biomarkers for Gastric and Gastroesophageal Junction Adenocarcinoma: Why PD-L1 Testing May Not Be Enough.
Weinberg BA; Xiu J; Hwang JJ; Shields AF; Salem ME; Marshall JL
Oncologist; 2018 Oct; 23(10):1171-1177. PubMed ID: 29703766
[TBL] [Abstract][Full Text] [Related]
32. Harmonization of programmed death-ligand 1 immunohistochemistry and mRNA expression scoring in metastatic melanoma: a multicentre analysis.
Darmon-Novello M; Adam J; Lamant L; Battistella M; Ortonne N; Balme B; de la Fouchardière A; Chaltiel L; Gerard E; Franchet C; Vergier B
Histopathology; 2022 Jun; 80(7):1091-1101. PubMed ID: 35322452
[TBL] [Abstract][Full Text] [Related]
33. Comparison of PD-L1 immunohistochemical assays in advanced gastric adenocarcinomas using endoscopic biopsy and paired resected specimens.
Kim SW; Jeong G; Ryu MH; Park YS
Pathology; 2021 Aug; 53(5):586-594. PubMed ID: 33546812
[TBL] [Abstract][Full Text] [Related]
34. PD-L1 Expression Harmonization in Gastric Cancer Using 22C3 PharmDx and SP263 Assays.
Dabbagh TZ; Sughayer MA
Appl Immunohistochem Mol Morphol; 2021 Jul; 29(6):462-466. PubMed ID: 33480602
[TBL] [Abstract][Full Text] [Related]
35. Interobserver agreement in programmed cell death-ligand 1 immunohistochemistry scoring in nonsmall cell lung carcinoma cytologic specimens.
Sinclair W; Kobalka P; Ren R; Beshai B; Lott Limbach AA; Wei L; Mei P; Li Z
Diagn Cytopathol; 2021 Feb; 49(2):219-225. PubMed ID: 33104298
[TBL] [Abstract][Full Text] [Related]
36. PD-L1 Assessment in Needle Core Biopsies of Non-Small Cell Lung Cancer: Interpathologist Agreement and Potential Associated Histopathological Features.
Hacihasanoglu E; Bambul Sigirci B; Usul G; Savli TC
Turk Patoloji Derg; 2024; 40(1):37-44. PubMed ID: 37614090
[TBL] [Abstract][Full Text] [Related]
37. Choice of PD-L1 immunohistochemistry assay influences clinical eligibility for gastric cancer immunotherapy.
Yeong J; Lum HYJ; Teo CB; Tan BKJ; Chan YH; Tay RYK; Choo JR; Jeyasekharan AD; Miow QH; Loo LH; Yong WP; Sundar R
Gastric Cancer; 2022 Jul; 25(4):741-750. PubMed ID: 35661944
[TBL] [Abstract][Full Text] [Related]
38. Discordant PD-L1 results between 28-8 and 22C3 assays are associated with outcomes of gastric cancer patients treated with nivolumab plus chemotherapy.
Kim HD; Shin J; Song IH; Hyung J; Lee H; Ryu MH; Park YS
Gastric Cancer; 2024 Jul; 27(4):819-826. PubMed ID: 38647978
[TBL] [Abstract][Full Text] [Related]
39. Programmed death-ligand 1 expression in carcinoma of unknown primary.
Kim HM; Koo JS
BMC Cancer; 2024 Jun; 24(1):689. PubMed ID: 38844907
[TBL] [Abstract][Full Text] [Related]
40. RUSSCO-RSP comparative study of immunohistochemistry diagnostic assays for PD-L1 expression in urothelial bladder cancer.
Zavalishina L; Tsimafeyeu I; Povilaitite P; Raskin G; Andreeva Y; Petrov A; Kharitonova E; Rumyantsev A; Pugach I; Frank G; Tjulandin S
Virchows Arch; 2018 Dec; 473(6):719-724. PubMed ID: 30209552
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
